Changzhou Qianhong Biopharma Co Ltd - ESG Rating & Company Profile powered by AI
Other companies in the scoring industry group for Changzhou Qianhong Biopharma Co Ltd are shownin the table. This assessment of Changzhou Qianhong Biopharma Co Ltd was assembled by All Street Sevva using proprietary artificial intelligence. This ESG score includes 17 United Nations SDGs including: 'No Poverty', 'Reduced Inequalities' and 'Life on Land'.
Changzhou Qianhong Biopharma Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Changzhou Qianhong Biopharma Co Ltd | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Changzhou Qianhong Biopharma Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Changzhou Qianhong Biopharma Co Ltd disclose current and historical energy intensity?
Does Changzhou Qianhong Biopharma Co Ltd report the average age of the workforce?
Does Changzhou Qianhong Biopharma Co Ltd reference operational or capital allocation in relation to climate change?
Does Changzhou Qianhong Biopharma Co Ltd disclose its ethnicity pay gap?
Does Changzhou Qianhong Biopharma Co Ltd disclose cybersecurity risks?
Does Changzhou Qianhong Biopharma Co Ltd offer flexible work?
Does Changzhou Qianhong Biopharma Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Changzhou Qianhong Biopharma Co Ltd disclose the number of employees in R&D functions?
Does Changzhou Qianhong Biopharma Co Ltd conduct supply chain audits?
Does Changzhou Qianhong Biopharma Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Changzhou Qianhong Biopharma Co Ltd conduct 360 degree staff reviews?
Does Changzhou Qianhong Biopharma Co Ltd disclose the individual responsible for D&I?
Does Changzhou Qianhong Biopharma Co Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Changzhou Qianhong Biopharma Co Ltd disclose current and / or historical scope 2 emissions?
Does Changzhou Qianhong Biopharma Co Ltd disclose water use targets?
Does Changzhou Qianhong Biopharma Co Ltd have careers partnerships with academic institutions?
Did Changzhou Qianhong Biopharma Co Ltd have a product recall in the last two years?
Does Changzhou Qianhong Biopharma Co Ltd disclose incidents of discrimination?
Does Changzhou Qianhong Biopharma Co Ltd allow for Work Councils/Collective Agreements to be formed?
Has Changzhou Qianhong Biopharma Co Ltd issued a profit warning in the past 24 months?
Does Changzhou Qianhong Biopharma Co Ltd disclose parental leave metrics?
Does Changzhou Qianhong Biopharma Co Ltd disclose climate scenario or pathway analysis?
Does Changzhou Qianhong Biopharma Co Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Changzhou Qianhong Biopharma Co Ltd disclose the pay ratio of women to men?
Does Changzhou Qianhong Biopharma Co Ltd support suppliers with sustainability related research and development?
Does Changzhou Qianhong Biopharma Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Changzhou Qianhong Biopharma Co Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Changzhou Qianhong Biopharma Co Ltd involved in embryonic stem cell research?
Does Changzhou Qianhong Biopharma Co Ltd disclose GHG and Air Emissions intensity?
Does Changzhou Qianhong Biopharma Co Ltd disclose its waste policy?
Does Changzhou Qianhong Biopharma Co Ltd report according to TCFD requirements?
Does Changzhou Qianhong Biopharma Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Changzhou Qianhong Biopharma Co Ltd disclose energy use targets?
Does Changzhou Qianhong Biopharma Co Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Changzhou Qianhong Biopharma Co Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Changzhou Qianhong Biopharma Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Changzhou Qianhong Biopharma CO.,LTD engages in the research and development, production, and sale of bio-pharmaceutical products with a focus on polysaccharides and enzymes in China. The company provides various API products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; kallidinogenase kallikrein for use in the treatment of microcirculation disorders; and heparinoid. It also offers a range of preparations, such as nadroparin calcium PFS, enoxaparin sodium PFS, dalteparin sodium PFS, and asparaginase and heparin sodium injections for use as anticoagulants. In addition, the company exports its products. Changzhou Qianhong Biopharma CO.,LTD was founded in 1971 and is headquartered in Changzhou, China.